Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy Journal Article


Author: Moskowitz, A. J.
Article Title: Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy
Abstract: The US Food and Drug Administration approval of brentuximab vedotin (BV) in 2011 marked an important milestone in the management of classical Hodgkin lymphoma (HL). Although initially approved for use in the relapsed or refractory setting, its high efficacy and favorable toxicity profile led to numerous studies evaluating BV in the front-line, second-line, and posttransplant settings. BV is now approved for use (in combination with chemotherapy) as frontline treatment of advanced-stage patients and as maintenance therapy following autologous stem cell transplant. Additional studies demonstrate its promise as second-line therapy and for elderly patients, as well. Although studies have demonstrated its promise in multiple settings, the ideal timing for use of BV is evolving. Studies evaluating individualized treatment strategies will ultimately define the optimal place for BV in HL treatment. © 2018 by The American Society of Hematology. All rights reserved.
Journal Title: Hematology-American Society of Hematology Education Program
Volume: 2018
Issue: 1
ISSN: 1520-4391
Publisher: American Society of Hematology  
Date Published: 2018-11-30
Start Page: 207
End Page: 212
Language: English
DOI: 10.1182/asheducation-2018.1.207
PROVIDER: scopus c2 - 30504312
PMCID: PMC6246031
PUBMED: 30504312
DOI/URL:
Notes: Hematology Am Soc Hematol Educ Program -- Export Date: 2 January 2019 -- Review -- Source: Scopus C2 - 30504312
Altmetric Score
MSK Authors
  1. Alison Moskowitz
    136 Moskowitz